Fig. 4.

Median treatment duration from 2L irinotecan-based chemotherapy plus antiangiogenic drugs by duration of 1L therapy (a), CRC surgery before the index date (b), liver surgery during 1L therapy (c), NSAID prescription before starting 2L therapy (d), CRC sidedness (e), antihypertensive prescription during 2L therapy (f), and proteinuria tests during 2L therapy (g). For f and g, only patients who received two or more 2L prescriptions for antiangiogenic drugs were included in the analyses in order to evaluate the use of these concomitant therapies during 2L therapy. 1L/2L first-line/second-line, CI confidence interval, CRC colorectal cancer, mo months, NA not applicable, NSAID nonsteroidal anti-inflammatory drug